Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)01808-7/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_infocusoncology_esmo24&_hsenc=p2ANqtz--3gakInXeR11EtLVAOWtUXvA_EGMguysYn6HEbrwbl7wlmK1B5RA5kBITT11PlYV_TH1RCpxEWlTPg6VSi9m2aJ18wwg&_hsmi=325179166&utm_content=325179166&utm_source=hs_email